Journal article
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Abstract
BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
METHODS: We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body …
Authors
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao L-L; Miao Y
Journal
New England Journal of Medicine, Vol. 375, No. 20, pp. 1946–1960
Publisher
Massachusetts Medical Society
Publication Date
November 17, 2016
DOI
10.1056/nejmoa1602773
ISSN
0028-4793